QUARTERLY REPORT

Q3 2022 — Form 10-Q

Q3 2022PDF · 34 pages490 KB
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2022
OR
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from 	to
Commission File No. 1-2189
ABBOTT LABORATORIES
An Illinois Corporation 	I.R.S. Employer Identification No.
36-0698440
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
Telephone: (224) 667-6100
Securities Registered Pursuant to Section 12(b) of the Act:
Title of Each Class 	Trading Symbol(s) 	Name of Each Exchange on Which Registered
Common Shares, Without Par Value 	ABT 	New York Stock Exchange
Chicago Stock Exchange, Inc.
Indicate by check mark whether the registrant: (l) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of l934
during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of
Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an
emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth
company” in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer x 	Accelerated Filer o
Non-Accelerated Filer o 	Smaller reporting company o
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
As of September 30, 2022, Abbott Laboratories had 1,743,573,777 common shares without par value outstanding.

-- 1 of 34 --

Table of Contents
Abbott Laboratories
Table of Contents
Part I - Financial Information
Page
Item 1. Financial Statements and Supplementary Data
Condensed Consolidated Statement of Earnings 	3
Condensed Consolidated Statement of Comprehensive Income 	4
Condensed Consolidated Balance Sheet 	5
Condensed Consolidated Statement of Shareholders’ Investment 	6
Condensed Consolidated Statement of Cash Flows 	8
Notes to the Condensed Consolidated Financial Statements 	9
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 	22
Item 4. Controls and Procedures 	28
Part II - Other Information 	28
Item 1. Legal Proceedings 	28
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 	28
Item 6. Exhibits 	29
Signature 	30
2

-- 2 of 34 --

Table of Contents
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited)
(dollars in millions except per share data; shares in thousands)
Three Months Ended 	Nine Months Ended
September 30 	September 30
2022 	2021 	2022 	2021
Net sales 	$ 	10,410 $ 	10,928 $ 	33,562 $ 	31,607
Cost of products sold, excluding amortization of intangible assets 	4,629 	4,423 	14,549 	13,771
Amortization of intangible assets 	498 	520 	1,517 	1,533
Research and development 	782 	672 	2,163 	1,980
Selling, general and administrative 	2,731 	2,767 	8,275 	8,276
Total operating cost and expenses 	8,640 	8,382 	26,504 	25,560
Operating earnings 	1,770 	2,546 	7,058 	6,047
Interest expense 	141 	133 	404 	402
Interest (income) 	(55) 	(10) 	(95) 	(32)
Net foreign exchange (gain) loss 	19 	4 	16 	7
Other (income) expense, net 	(93) 	(74) 	(253) 	(214)
Earnings before taxes 	1,758 	2,493 	6,986 	5,884
Taxes on earnings 	323 	393 	1,086 	802
Net Earnings 	$ 	1,435 $ 	2,100 $ 	5,900 $ 	5,082
Basic Earnings Per Common Share 	$ 	0.82 $ 	1.18 $ 	3.35 $ 	2.85
Diluted Earnings Per Common Share 	$ 	0.81 $ 	1.17 $ 	3.32 $ 	2.83
Average Number of Common Shares Outstanding Used for Basic Earnings Per
Common Share 	1,752,968 	1,774,516 	1,756,209 	1,776,870
Dilutive Common Stock Options 	10,685 	14,483 	11,638 	14,407
Average Number of Common Shares Outstanding Plus Dilutive Common Stock
Options 	1,763,653 	1,788,999 	1,767,847 	1,791,277
Outstanding Common Stock Options Having No Dilutive Effect 	5,445 	2,740 	2,655 	2,694
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
3

-- 3 of 34 --

Table of Contents
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Comprehensive Income
(Unaudited)
(dollars in millions)
Three Months Ended 	Nine Months Ended
September 30 	September 30
2022 	2021 	2022 	2021
Net Earnings 	$ 	1,435 $ 	2,100 $ 	5,900 $ 	5,082
Foreign currency translation gain (loss) adjustments 	(1,008) 	(391) 	(1,429) 	(762)
Net actuarial gains (losses) and amortization of net actuarial losses and prior
service costs and credits, net of taxes of $11 and $36 in 2022 and $18 and $54
in 2021 	56 	78 	172 	211
Net gains (losses) for derivative instruments designated as cash flow hedges and
other, net of taxes of $50 and $96 in 2022 and $50 and $98 in 2021 	213 	139 	186 	257
Other comprehensive income (loss) 	(739) 	(174) 	(1,071) 	(294)
Comprehensive Income 	$ 	696 $ 	1,926 $ 	4,829 $ 	4,788
September 30,
2022 December 31,
2021
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:
Cumulative foreign currency translation (loss) adjustments 	$ 	(7,268) $ 	(5,839)
Net actuarial (losses) and prior service (costs) and credits 	(2,498) 	(2,670)
Cumulative gains (losses) on derivative instruments designated as cash flow hedges and other 	321 	135
Accumulated other comprehensive income (loss) 	$ 	(9,445) $ 	(8,374)
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
4

-- 4 of 34 --

Table of Contents
Abbott Laboratories and Subsidiaries
Condensed Consolidated Balance Sheet
(Unaudited)
(dollars in millions)
September 30,
2022
December 31,
2021
Assets
Current Assets:
Cash and cash equivalents 	$ 	9,594 $ 	9,799
Short-term investments 	313 	450
Trade receivables, less allowances of $520 in 2022 and $519 in 2021 	6,408 	6,487
Inventories:
Finished products 	3,407 	3,081
Work in process 	726 	694
Materials 	1,601 	1,382
Total inventories 	5,734 	5,157
Prepaid expenses and other receivables 	2,796 	2,346
Total Current Assets 	24,845 	24,239
Investments 	764 	816
Property and equipment, at cost 	19,306 	19,364
Less: accumulated depreciation and amortization 	10,617 	10,405
Net property and equipment 	8,689 	8,959
Intangible assets, net of amortization 	10,850 	12,739
Goodwill 	22,284 	23,231
Deferred income taxes and other assets 	5,369 	5,212
$ 	72,801 $ 	75,196
Liabilities and Shareholders’ Investment
Current Liabilities:
Trade accounts payable 	$ 	4,133 $ 	4,408
Salaries, wages and commissions 	1,426 	1,625
Other accrued liabilities 	5,475 	5,181
Dividends payable 	820 	831
Income taxes payable 	394 	306
Current portion of long-term debt 	1,117 	754
Total Current Liabilities 	13,365 	13,105
Long-term debt 	15,297 	17,296
Post-employment obligations, deferred income taxes and other long-term liabilities 	8,255 	8,771
Commitments and Contingencies
Shareholders’ Investment:
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued 	— 	—
Common shares, without par value Authorized — 2,400,000,000 shares
Issued at stated capital amount — Shares: 2022: 1,985,919,440; 2021: 1,985,273,421 	24,560 	24,470
Common shares held in treasury, at cost — Shares: 2022: 242,345,663; 2021: 221,191,228 	(14,555) 	(11,822)
Earnings employed in the business 	35,115 	31,528
Accumulated other comprehensive income (loss) 	(9,445) 	(8,374)
Total Abbott Shareholders’ Investment 	35,675 	35,802
Noncontrolling Interests in Subsidiaries 	209 	222
Total Shareholders’ Investment 	35,884 	36,024
$ 	72,801 $ 	75,196
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
5

-- 5 of 34 --

Table of Contents
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Shareholders’ Investment
(Unaudited)
(in millions except shares and per share data)
Three Months Ended September 30
2022 	2021
Common Shares:
Balance at June 30
Shares: 2022: 1,985,676,735; 2021: 1,982,553,488 	$ 	24,429 $ 	24,153
Issued under incentive stock programs
Shares: 2022: 242,705; 2021: 550,366 	12 	26
Share-based compensation 	123 	113
Issuance of restricted stock awards 	(4) 	(7)
Balance at September 30
Shares: 2022: 1,985,919,440; 2021: 1,983,103,854 	$ 	24,560 $ 	24,285
Common Shares Held in Treasury:
Balance at June 30
Shares: 2022: 234,456,992; 2021: 209,736,139 	$ 	(13,720) $ 	(10,340)
Issued under incentive stock programs
Shares: 2022: 528,436; 2021: 545,860 	31 	26
Purchased
Shares: 2022: 8,417,107; 2021: 5,626,606 	(866) 	(685)
Balance at September 30
Shares: 2022: 242,345,663; 2021: 214,816,885 	$ 	(14,555) $ 	(10,999)
Earnings Employed in the Business:
Balance at June 30 	$ 	34,487 $ 	29,053
Net earnings 	1,435 	2,100
Cash dividends declared on common shares (per share — 2022: $0.47; 2021: $0.45) 	(822) 	(799)
Effect of common and treasury share transactions 	15 	22
Balance at September 30 	$ 	35,115 $ 	30,376
Accumulated Other Comprehensive Income (Loss):
Balance at June 30 	$ 	(8,706) $ 	(9,066)
Other comprehensive income (loss) 	(739) 	(174)
Balance at September 30 	$ 	(9,445) $ 	(9,240)
Noncontrolling Interests in Subsidiaries:
Balance at June 30 	$ 	226 $ 	229
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases 	(17) 	(13)
Balance at September 30 	$ 	209 $ 	216
The accompanying notes to condensed consolidated financial statements are an integral part of this statement.
6

-- 6 of 34 --

Table of Contents
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Shareholders’ Investment
(Unaudited)
(in millions except shares and per share data)
Nine Months Ended September 30
2022 	2021
Common Shares:
Balance at January 1
Shares: 2022: 1,985,273,421; 2021: 1,981,156,896 	$ 	24,470 $ 	24,145
Issued under incentive stock programs
Shares: 2022: 646,019; 2021: 1,946,958 	36 	91
Share-based compensation 	572 	536
Issuance of restricted stock awards 	(518) 	(487)
Balance at September 30
Shares: 2022: 1,985,919,440; 2021: 1,983,103,854 	$ 	24,560 $ 	24,285
Common Shares Held in Treasury:
Balance at January 1
Shares: 2022: 221,191,228; 2021: 209,926,622 	$ 	(11,822) $ 	(10,042)
Issued under incentive stock programs
Shares: 2022: 4,808,575; 2021: 5,524,291 	261 	265
Purchased
Shares: 2022: 25,963,010; 2021: 10,414,554 	(2,994) 	(1,222)
Balance at September 30
Shares: 2022: 242,345,663; 2021: 214,816,885 	$ 	(14,555) $ 	(10,999)
Earnings Employed in the Business:
Balance at January 1 	$ 	31,528 $ 	27,627
Net earnings 	5,900 	5,082
Cash dividends declared on common shares (per share — 2022: $1.41; 2021: $1.35) 	(2,475) 	(2,403)
Effect of common and treasury share transactions 	162 	70
Balance at September 30 	$ 	35,115 $ 	30,376
Accumulated Other Comprehensive Income (Loss):
Balance at January 1 	$ 	(8,374) $ 	(8,946)
Other comprehensive income (loss) 	(1,071) 	(294)
Balance at September 30 	$ 	(9,445) $ 	(9,240)
Noncontrolling Interests in Subsidiaries:
Balance at January 1 	$ 	222 $ 	219
Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases 	(13) 	(3)
Balance at September 30 	$ 	209 $ 	216
The accompanying notes to condensed consolidated financial statements are an integral part of this statement.
7

-- 7 of 34 --

Table of Contents
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Cash Flows
(Unaudited)
(dollars in millions)
Nine Months Ended September 30
2022 	2021
Cash Flow From (Used in) Operating Activities:
Net earnings 	$ 	5,900 $ 	5,082
Adjustments to reconcile net earnings to net cash from operating activities —
Depreciation 	943 	1,122
Amortization of intangible assets 	1,517 	1,533
Share-based compensation 	570 	534
Trade receivables 	(409) 	(194)
Inventories 	(1,224) 	(471)
Other, net 	(42) 	(140)
Net Cash From Operating Activities 	7,255 	7,466
Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment 	(1,167) 	(1,271)
Acquisitions of businesses and technologies, net of cash acquired 	— 	(187)
Proceeds from business dispositions 	48 	134
Sales (purchases) of other investment securities, net 	(3) 	(27)
Other 	14 	14
Net Cash From (Used in) Investing Activities 	(1,108) 	(1,337)
Cash Flow From (Used in) Financing Activities:
Net borrowings (repayments) of short-term debt and other 	37 	(7)
Proceeds from issuance of long-term debt 	7 	—
Repayments of long-term debt 	(753) 	(45)
Purchases of common shares 	(3,110) 	(1,325)
Proceeds from stock options exercised 	126 	173
Dividends paid 	(2,486) 	(2,404)
Net Cash From (Used in) Financing Activities 	(6,179) 	(3,608)
Effect of exchange rate changes on cash and cash equivalents 	(173) 	(57)
Net Increase (Decrease) in Cash and Cash Equivalents 	(205) 	2,464
Cash and Cash Equivalents, Beginning of Year 	9,799 	6,838
Cash and Cash Equivalents, End of Period 	$ 	9,594 $ 	9,302
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
8

-- 8 of 34 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)
Note 1 — Basis of Presentation
The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and
Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However,
in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial
position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s
Annual Report on Form 10-K for the year ended December 31, 2021. The condensed consolidated financial statements include the accounts of the parent
company and subsidiaries, after elimination of intercompany transactions.
Note 2 — Revenue
Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Abbott has four
reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
The following tables provide detail by sales category:
Three Months Ended September 30, 2022 	Three Months Ended September 30, 2021
(in millions) 	U.S. 	Int’l 	Total 	U.S. 	Int’l 	Total
Established Pharmaceutical Products —
Key Emerging Markets 	$ 	— $ 	993 $ 	993 $ 	— $ 	936 $ 	936
Other 	— 	333 	333 	— 	329 	329
Total 	— 	1,326 	1,326 	— 	1,265 	1,265
Nutritionals —
Pediatric Nutritionals 	357 	470 	827 	586 	514 	1,100
Adult Nutritionals 	329 	639 	968 	333 	675 	1,008
Total 	686 	1,109 	1,795 	919 	1,189 	2,108
Diagnostics —
Core Laboratory 	281 	938 	1,219 	291 	1,001 	1,292
Molecular 	65 	118 	183 	162 	183 	345
Point of Care 	92 	35 	127 	100 	35 	135
Rapid Diagnostics 	1,303 	839 	2,142 	1,394 	746 	2,140
Total 	1,741 	1,930 	3,671 	1,947 	1,965 	3,912
Medical Devices —
Rhythm Management 	263 	270 	533 	266 	305 	571
Electrophysiology 	225 	244 	469 	192 	293 	485
Heart Failure 	177 	51 	228 	170 	59 	229
Vascular 	213 	393 	606 	219 	425 	644
Structural Heart 	207 	213 	420 	177 	215 	392
Neuromodulation 	156 	36 	192 	149 	41 	190
Diabetes Care 	423 	744 	1,167 	323 	798 	1,121
Total 	1,664 	1,951 	3,615 	1,496 	2,136 	3,632
Other 	3 	— 	3 	6 	5 	11
Total 	$ 	4,094 $ 	6,316 $ 	10,410 $ 	4,368 $ 	6,560 $ 	10,928
9

-- 9 of 34 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)
Note 2 — Revenue (Continued)
Nine Months Ended September 30, 2022 	Nine Months Ended September 30, 2021
(in millions) 	U.S. 	Int’l 	Total 	U.S. 	Int’l 	Total
Established Pharmaceutical Products —
Key Emerging Markets 	$ 	— $ 	2,826 $ 	2,826 $ 	— $ 	2,672 $ 	2,672
Other 	— 	870 	870 	— 	843 	843
Total 	— 	3,696 	3,696 	— 	3,515 	3,515
Nutritionals —
Pediatric Nutritionals 	1,108 	1,491 	2,599 	1,622 	1,637 	3,259
Adult Nutritionals 	1,016 	2,027 	3,043 	1,006 	1,987 	2,993
Total 	2,124 	3,518 	5,642 	2,628 	3,624 	6,252
Diagnostics —
Core Laboratory 	836 	2,788 	3,624 	845 	2,935 	3,780
Molecular 	308 	507 	815 	431 	651 	1,082
Point of Care 	284 	110 	394 	289 	112 	401
Rapid Diagnostics 	5,523 	2,923 	8,446 	3,178 	2,732 	5,910
Total 	6,951 	6,328 	13,279 	4,743 	6,430 	11,173
Medical Devices —
Rhythm Management 	775 	830 	1,605 	776 	881 	1,657
Electrophysiology 	667 	773 	1,440 	580 	823 	1,403
Heart Failure 	523 	167 	690 	483 	167 	650
Vascular 	650 	1,228 	1,878 	684 	1,292 	1,976
Structural Heart 	604 	667 	1,271 	537 	654 	1,191
Neuromodulation 	456 	112 	568 	460 	124 	584
Diabetes Care 	1,165 	2,320 	3,485 	865 	2,292 	3,157
Total 	4,840 	6,097 	10,937 	4,385 	6,233 	10,618
Other 	8 	— 	8 	31 	18 	49
Total 	$ 	13,923 $ 	19,639 $ 	33,562 $ 	11,787 $ 	19,820 $ 	31,607
Remaining Performance Obligations
As of September 30, 2022, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially
unsatisfied) was approximately $3.9 billion in the Diagnostics segment and approximately $433 million in the Medical Devices segment. Abbott expects to
recognize revenue on approximately 60 percent of these remaining performance obligations over the next 24 months, approximately 16 percent over the
subsequent 12 months and the remainder thereafter.
These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended
warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has
applied the practical expedient described in Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 606-10-50-14 and
has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.
10

-- 10 of 34 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)
Note 2 — Revenue (Continued)
Other Contract Assets and Liabilities
Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets
primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and
end of the period, as well as the changes in the balance, were not significant.
Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise
primarily in the Medical Devices reportable segment when payment is received upfront for various multi-period extended service arrangements.
Changes in the contract liabilities during the period are as follows:
(in millions)
Contract Liabilities:
Balance at December 31, 2021 	$ 	520
Unearned revenue from cash received during the period 	466
Revenue recognized related to contract liability balance 	(508)
Balance at September 30, 2022 	$ 	478
Note 3 — Supplemental Financial Information
Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation
of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating
securities. Net earnings allocated to common shares for the three months ended September 30, 2022 and 2021 were $1.429 billion and $2.092 billion,
respectively, and for the nine months ended September 30, 2022 and 2021 were $5.876 billion and $5.061 billion, respectively.
Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first nine months of 2022 includes $362
million of pension contributions and the payment of cash taxes of approximately $987 million. The first nine months of 2021 includes $366 million of
pension contributions and the payment of cash taxes of approximately $990 million.
The following summarizes the activity for the first nine months of 2022 related to the allowance for doubtful accounts as of September 30, 2022:
(in millions)
Allowance for Doubtful Accounts:
Balance at December 31, 2021 	$ 	313
Provisions/charges to income 	10
Amounts charged off and other deductions 	(49)
Balance at September 30, 2022 	$ 	274
The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. Abbott
considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts, including the aging of the accounts and aging
trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-
looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.
11

-- 11 of 34 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)
Note 3 — Supplemental Financial Information (Continued)
The components of long-term investments as of September 30, 2022 and December 31, 2021 are as follows:
(in millions) September 30,
2022
December 31,
2021
Long-term Investments:
Equity securities 	$ 	604 $ 	748
Other 	160 	68
Total 	$ 	764 $ 	816
The decrease in Abbott’s long-term investments as of September 30, 2022 versus the balance as of December 31, 2021 primarily relates to a decrease in the
value of investments held in a rabbi trust and the impact of equity method investment losses partially offset by an investment in long-term time deposits.
Abbott’s equity securities as of September 30, 2022, include $285 million of investments in mutual funds that are held in a rabbi trust and were acquired as
part of the St. Jude Medical, Inc. (St. Jude Medical) business acquisition. These investments, which are specifically designated as available for the purpose
of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of
insolvency.
Abbott also holds certain investments as of September 30, 2022 with a carrying value of $228 million that are accounted for under the equity method of
accounting and other equity investments with a carrying value of approximately $83 million that do not have a readily determinable fair value.
In September 2021, Abbott acquired 100 percent of Walk Vascular, LLC (Walk Vascular), a commercial-stage medical device company with a minimally
invasive thrombectomy system designed to remove peripheral blood clots. The purchase price, the allocation of acquired assets and liabilities, and the
revenue and net income contributed by Walk Vascular since the date of acquisition are not material to Abbott’s condensed consolidated financial
statements.
Note 4 — Changes In Accumulated Other Comprehensive Income (Loss)
The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:
Three Months Ended September 30
Cumulative Foreign
Currency Translation
(Loss) Adjustments
Net Actuarial (Losses) and
Prior Service (Costs) and
Credits
Cumulative Gains (Losses)
on Derivative Instruments
Designated as Cash Flow
Hedges and Other
(in millions) 	2022 	2021 	2022 	2021 	2022 	2021
Balance at June 30 	$ 	(6,260) $ 	(5,230) $ 	(2,554) $ 	(3,738) $ 	108 $ 	(98)
Other comprehensive income (loss) before
reclassifications 	(1,008) 	(391) 	15 	16 	278 	70
Amounts reclassified from accumulated
other comprehensive income 	— 	— 	41 	62 	(65) 	69
Net current period comprehensive income
(loss) 	(1,008) 	(391) 	56 	78 	213 	139
Balance at September 30 	$ 	(7,268) $ 	(5,621) $ 	(2,498) $ 	(3,660) $ 	321 $ 	41
12

-- 12 of 34 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)
Note 4 — Changes In Accumulated Other Comprehensive Income (Loss) (Continued)
Nine Months Ended September 30
Cumulative Foreign
Currency Translation
(Loss) Adjustments
Net Actuarial (Losses) and
Prior Service (Costs) and
Credits
Cumulative Gains (Losses)
on Derivative Instruments
Designated as Cash Flow
Hedges and Other
(in millions) 	2022 	2021 	2022 	2021 	2022 	2021
Balance at January 1 	$ 	(5,839) $ 	(4,859) $ 	(2,670) $ 	(3,871) $ 	135 $ 	(216)
Other comprehensive income (loss) before
reclassifications 	(1,429) 	(762) 	45 	26 	289 	138
Amounts reclassified from accumulated
other comprehensive income 	— 	— 	127 	185 	(103) 	119
Net current period comprehensive income
(loss) 	(1,429) 	(762) 	172 	211 	186 	257
Balance at September 30 	$ 	(7,268) $ 	(5,621) $ 	(2,498) $ 	(3,660) $ 	321 $ 	41
Reclassified amounts for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost are included as a component of
net periodic benefit costs; see Note 11 for additional details.
Note 5 — Goodwill and Intangible Assets
The total amount of goodwill reported was $22.3 billion at September 30, 2022 and $23.2 billion at December 31, 2021. Foreign currency translation
adjustments decreased goodwill by approximately $946 million in the first nine months of 2022. The amount of goodwill related to reportable segments at
September 30, 2022 was $2.6 billion for the Established Pharmaceutical Products segment, $286 million for the Nutritional Products segment, $3.5 billion
for the Diagnostic Products segment, and $15.9 billion for the Medical Devices segment. There was no reduction of goodwill relating to impairments in the
first nine months of 2022.
The gross amount of amortizable intangible assets, primarily product rights and technology, was $26.9 billion and $27.7 billion as of September 30, 2022
and December 31, 2021, respectively. Accumulated amortization was $16.9 billion and $15.9 billion as of September 30, 2022 and December 31, 2021,
respectively. Foreign currency translation adjustments decreased intangible assets by $250 million in the first nine months of 2022. Abbott’s estimated
annual amortization expense for intangible assets is approximately $2.1 billion in 2022, $2.0 billion in 2023, $1.9 billion in 2024, $1.7 billion in 2025 and
$1.6 billion in 2026.
Indefinite-lived intangible assets, which relate to in-process R&D (IPR&D) acquired in a business combination, were approximately $807 million as of
September 30, 2022 and $919 million as of December 31, 2021. In the third quarter of 2022, $111 million of impairment charges were recorded on the
Research and development line of the Condensed Consolidated Statement of Earnings related to certain IPR&D intangible assets associated with the
Medical Devices business segment.
Note 6 — Restructuring Plans
On May 27, 2021, Abbott management approved a restructuring plan related to its Diagnostic Products segment to align its manufacturing network for
COVID-19 diagnostic tests with changes in the second quarter in projected testing demand driven by several factors, including significant reductions in
cases in the U.S. and other major developed countries, the accelerated rollout of COVID-19 vaccines globally and the U.S. health authority’s updated
guidance on testing for fully vaccinated individuals. In the second quarter of 2021, Abbott recorded charges of $499 million under this plan in Cost of
products sold. The charge recognized in the second quarter of 2021 included fixed asset write-downs of $80 million, inventory-related charges of $248
million, and other exit costs, which included contract cancellations and employee-related costs of $171 million.
13

-- 13 of 34 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)
Note 6 — Restructuring Plans (Continued)
In the second half of 2021, as the Delta and Omicron variants of COVID-19 spread and the number of new COVID-19 cases increased significantly,
particularly in the U.S., demand for rapid COVID-19 tests increased significantly. As a result, in the second half of 2021, Abbott sold approximately $181
million of inventory that was previously estimated to have no net realizable value under the second quarter of 2021 restructuring action. In addition, the
estimate of other exit costs was reduced by a net $58 million as Abbott fulfilled its purchase obligations under certain contracts for which a liability was
recorded in the second quarter of 2021 or Abbott settled with the counterparty in the second half of 2021.
The following summarizes the activity related to this restructuring action and the status of the related accruals as of September 30, 2022:
(in millions)
Inventory-
Related
Charges Fixed Asset
Write-Downs
Other Exit
Costs 	Total
Restructuring charges recorded in 2021 	$ 	248 $ 	80 $ 	113 $ 	441
Payments 	— 	— 	(90) 	(90)
Other non-cash 	(248) 	(80) 	— 	(328)
Accrued balance at December 31, 2021 	— 	— 	23 	23
Payments and other adjustments 	— 	— 	(10) 	(10)
Accrued balance at September 30, 2022 	$ 	— $ 	— $ 	13 $ 	13
In 2021, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in Abbott’s diagnostic, established
pharmaceutical, and nutritional businesses. In 2022 and 2021, Abbott management approved plans to streamline operations in its medical devices segment.
Abbott recorded employees-related severance and other charges of approximately $12 million in the first nine months of 2022 of which approximately
$5 million was recorded in Cost of products sold, approximately $2 million was recorded in Research and development, and approximately $5 million was
recorded in Selling, general and administrative expense.
The following summarizes the activity for these restructurings:
(in millions)
Restructuring charges recorded in 2021 	$ 	68
Payments and other adjustments 	(7)
Accrued balance at December 31, 2021 	61
Restructuring charges recorded in 2022 	12
Payments and other adjustments 	(39)
Accrued balance at September 30, 2022 	$ 	34
14

-- 14 of 34 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)
Note 7 — Incentive Stock Program
In the first nine months of 2022, Abbott granted 2,634,647 stock options, 514,205 restricted stock awards and 5,427,697 restricted stock units under its
incentive stock program. At September 30, 2022, approximately 87 million shares were reserved for future grants. Information regarding the number of
options outstanding and exercisable at September 30, 2022 is as follows:
Outstanding 	Exercisable
Number of shares 	29,048,449 	23,310,464
Weighted average remaining life (years) 	5.4 	4.6
Weighted average exercise price 	$ 	70.22 $ 	59.69
Aggregate intrinsic value (in millions) 	$ 	901 $ 	890
The total unrecognized share-based compensation cost at September 30, 2022 amounted to approximately $600 million which is expected to be recognized
over the next three years.
Note 8 — Debt and Lines of Credit
On March 15, 2022, Abbott repaid the $750 million outstanding principal amount of its 2.55% Notes upon maturity.
Note 9 — Financial Instruments, Derivatives and Fair Value Measures
Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates
primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross
notional amounts totaling $7.9 billion at September 30, 2022 and $8.6 billion at December 31, 2021, are designated as cash flow hedges of the variability
of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of September 30, 2022 will be
included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months.
Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables
and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the
functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in
exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are
primarily the U.S. dollar and European currencies. At September 30, 2022 and December 31, 2021, Abbott held the gross notional amounts of $10.3 billion
and $12.2 billion, respectively, of such foreign currency forward exchange contracts.
Abbott has designated a yen-denominated, 5-year term loan of approximately $413 million and $521 million as of September 30, 2022 and December 31,
2021, respectively, as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign
exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.
Abbott is a party to interest rate hedge contracts with notional values totaling approximately $2.9 billion at September 30, 2022 and December 31, 2021 to
manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of
fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable
rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.
15

-- 15 of 34 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)
Note 9 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
The following table summarizes the amounts and location of certain derivative financial instruments as of September 30, 2022 and December 31, 2021:
Fair Value - Assets 	Fair Value - Liabilities
(in millions) September 30,
2022
Dec. 31,
2021 	Balance Sheet Caption September 30,
2022
Dec. 31,
2021 	Balance Sheet Caption
Interest rate swaps designated as fair value
hedges
$ 	— $ 	87 Deferred income
taxes and other assets
$ 	166 $ 	— Post-employment
obligations, deferred
income taxes and
other long-term
liabilities
Foreign currency forward exchange
contracts:
Hedging instruments 	760 	222 Prepaid expenses and
other receivables
66 	65 Other accrued
liabilities
Others not designated as hedges 	148 	70 Prepaid expenses and
other receivables
141 	32 Other accrued
liabilities
Debt designated as a hedge of net
investment in a foreign subsidiary
— 	— n/a 	413 	521 Long-term debt
$ 	908 $ 	379 	$ 	786 $ 	618
The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative
financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three and nine months ended
September 30, 2022 and 2021.
Gain (loss) Recognized in Other
Comprehensive Income (loss) Income (expense) and Gain (loss)
Reclassified into Income
Three Months
Ended September 30 Nine Months
Ended September 30 Three Months
Ended September 30 Nine Months
Ended September 30
(in millions) 	2022 	2021 	2022 	2021 	2022 	2021 	2022 	2021 Income Statement
Caption
Foreign currency forward
exchange contracts
designated as cash flow
hedges
$ 	350 $ 	96 $ 	442 $ 	142 $ 	79 $ 	(92) $ 	149 $ 	(207) Cost of products
sold
Debt designated as a hedge
of net investment in a
foreign subsidiary
24 	4 	108 	41 	— 	— 	— 	— n/a
Interest rate swaps
designated as fair value
hedges
n/a 	n/a 	n/a 	n/a 	(85) 	(14) 	(253) 	(81) Interest expense
16

-- 16 of 34 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)
Note 9 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
Losses of $27 million and $18 million were recognized in the three months ended September 30, 2022 and 2021, respectively, related to foreign currency
forward exchange contracts not designated as a hedge. Gains of $225 million and $15 million were recognized in the nine months ended September 30,
2022 and 2021, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the
Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line.
The carrying values and fair values of certain financial instruments as of September 30, 2022 and December 31, 2021 are shown in the following table. The
carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major
international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.
September 30, 2022 	December 31, 2021
(in millions) Carrying
Value
Fair
Value
Carrying
Value
Fair
Value
Long-term Investment Securities:
Equity securities 	$ 	604 $ 	604 $ 	748 $ 	748
Other 	160 	160 	68 	68
Total Long-term Debt 	(16,414) 	(15,821) 	(18,050) 	(21,152)
Foreign Currency Forward Exchange Contracts:
Receivable position 	908 	908 	292 	292
(Payable) position 	(207) 	(207) 	(97) 	(97)
Interest Rate Hedge Contracts:
Receivable position 	— 	— 	87 	87
(Payable) position 	(166) 	(166) 	— 	—
The fair value of the debt was determined based on significant other observable inputs, including current interest rates.
17

-- 17 of 34 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)
Note 9 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:
Basis of Fair Value Measurement
(in millions)
Outstanding
Balances
Quoted
Prices in
Active
Markets
Significant
Other
Observable
Inputs
Significant
Unobservable
Inputs
September 30, 2022:
Equity securities 	$ 	293 $ 	293 $ 	— $ 	—
Foreign currency forward exchange contracts 	908 	— 	908 	—
Total Assets 	$ 	1,201 $ 	293 $ 	908 $ 	—
Fair value of hedged long-term debt 	$ 	2,685 $ 	— $ 	2,685 $ 	—
Interest rate swap derivative financial instruments 	166 	— 	166 	—
Foreign currency forward exchange contracts 	207 	— 	207 	—
Contingent consideration related to business combinations 	138 	— 	— 	138
Total Liabilities 	$ 	3,196 $ 	— $ 	3,058 $ 	138
December 31, 2021:
Equity securities 	$ 	402 $ 	402 $ 	— $ 	—
Interest rate swap derivative financial instruments 	87 	— 	87 	—
Foreign currency forward exchange contracts 	292 	— 	292 	—
Total Assets 	$ 	781 $ 	402 $ 	379 $ 	—
Fair value of hedged long-term debt 	$ 	2,926 $ 	— $ 	2,926 $ 	—
Foreign currency forward exchange contracts 	97 	— 	97 	—
Contingent consideration related to business combinations 	130 	— 	— 	130
Total Liabilities 	$ 	3,153 $ 	— $ 	3,023 $ 	130
The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative
instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based
on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on
independent appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value.
Note 10 — Litigation and Environmental Matters
Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto
Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded
an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is
expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.
18

-- 18 of 34 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)
Note 10 — Litigation and Environmental Matters (Continued)
Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental
exposures to be from approximately $40 million to $50 million. The recorded accrual balance at September 30, 2022 for these proceedings and exposures
was approximately $45 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.”
Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the
outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect
on Abbott’s financial position, cash flows, or results of operations.
Note 11 — Post-Employment Benefits
Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are
recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings. Net cost recognized for the three and nine
months ended September 30 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:
Defined Benefit Plans 	Medical and Dental Plans
Three Months
Ended Sept. 30
Nine Months
Ended Sept. 30
Three Months
Ended Sept. 30
Nine Months
Ended Sept. 30
(in millions) 	2022 	2021 	2022 	2021 	2022 	2021 	2022 	2021
Service cost - benefits earned during
the period 	$ 	92 $ 	98 $ 	282 $ 	294 $ 	13 $ 	14 $ 	38 $ 	42
Interest cost on projected benefit
obligations 	74 	62 	225 	186 	9 	8 	27 	25
Expected return on plan assets 	(231) 	(211) 	(701) 	(633) 	(8) 	(6) 	(23) 	(20)
Net amortization of:
Actuarial loss, net 	58 	79 	174 	238 	2 	7 	8 	21
Prior service cost (credit) 	— 	— 	1 	1 	(6) 	(7) 	(18) 	(21)
Net cost (credit) 	$ 	(7) $ 	28 $ 	(19) $ 	86 $ 	10 $ 	16 $ 	32 $ 	47
Abbott funds its domestic defined benefit plans according to Internal Revenue Service funding limitations. International pension plans are funded
according to similar regulations. In the first nine months of 2022 and 2021, $362 million and $366 million, respectively, were contributed to defined benefit
plans. In the first nine months of 2022 and 2021, $28 million and $26 million, respectively, were contributed to the post-employment medical and dental
plans.
Note 12 — Taxes on Earnings
Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first nine months of 2022 and 2021, taxes
on earnings include approximately $36 million and $97 million, respectively, in excess tax benefits associated with share-based compensation. In the first
nine months of 2022, taxes on earnings also include approximately $20 million of tax expense as the result of the resolution of various tax positions related
to prior years.
Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount
of gross unrecognized tax benefits may decrease approximately $75 million to $100 million, including cash adjustments, within the next twelve months as
a result of concluding various domestic and international tax matters.
19

-- 19 of 34 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)
Note 13 — Segment Information
Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott’s products are generally
sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world.
Abbott’s reportable segments are as follows:
Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.
Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.
Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories, physician offices and
alternate-care testing sites. For segment reporting purposes, the Core Laboratory Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care
Diagnostics divisions are aggregated and reported as the Diagnostic Products segment.
Medical Devices — Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care
products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart,
Neuromodulation and Diabetes Care divisions are aggregated and reported as the Medical Devices segment.
Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are
on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a
measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at
predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated
to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.
20

-- 20 of 34 --

Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
September 30, 2022
(Unaudited)
Note 13 — Segment Information (Continued)
The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not
presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.
Net Sales to External Customers 	Operating Earnings
Three Months
Ended Sept. 30
Nine Months
Ended Sept. 30
Three Months
Ended Sept. 30
Nine Months
Ended Sept. 30
(in millions) 	2022 	2021 	2022 	2021 	2022 	2021 	2022 	2021
Established Pharmaceutical
Products 	$ 	1,326 $ 	1,265 $ 	3,696 $ 	3,515 $ 	331 $ 	293 $ 	831 $ 	682
Nutritional Products 	1,795 	2,108 	5,642 	6,252 	69 	431 	550 	1,388
Diagnostic Products 	3,671 	3,912 	13,279 	11,173 	1,352 	1,652 	5,631 	4,429
Medical Devices 	3,615 	3,632 	10,937 	10,618 	1,039 	1,160 	3,272 	3,375
Total Reportable Segments 	10,407 	10,917 	33,554 	31,558 	2,791 	3,536 	10,284 	9,874
Other 	3 	11 	8 	49
Net sales 	$ 	10,410 $ 	10,928 $ 	33,562 $ 	31,607
Corporate functions and benefit
plan costs 	(115) 	(204) 	(352) 	(450)
Net interest expense 	(86) 	(123) 	(309) 	(370)
Share-based compensation (a) 	(123) 	(114) 	(570) 	(534)
Amortization of intangible assets 	(498) 	(520) 	(1,517) 	(1,533)
Other, net (b) 	(211) 	(82) 	(550) 	(1,103)
Earnings before taxes 	$ 	1,758 $ 	2,493 $ 	6,986 $ 	5,884
______________________________________
(a) 	Approximately 45 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-
based awards.
(b) 	Other, net for the three and nine months ended September 30, 2022 includes $10 million and $172 million, respectively, of charges related to a voluntary recall
within the Nutritional Products segment and $111 million of charges related to the impairment of IPR&D intangible assets. Other, net for the three and nine months
ended September 30, 2022 and 2021 also includes integration costs associated with the acquisition of Alere and restructuring charges. Restructuring charges in
2021 include Abbott’s restructuring plan for its COVID-19 test manufacturing network. Other, net for the nine months ended September 30, 2021 also includes
costs related to certain litigation.
21

-- 21 of 34 --

Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Financial Review — Results of Operations
Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Patent protection
and licenses, technological and performance features, and inclusion of Abbott’s products under a contract most impact which products are sold; price
controls, competition and rebates most impact the net selling prices of products; and foreign currency translation impacts the measurement of net sales and
costs. Abbott’s primary products are medical devices, diagnostic testing products, nutritional products and branded generic pharmaceuticals.
The following tables detail sales by reportable segment for the three and nine months ended September 30. Percent changes are versus the prior year and
are based on unrounded numbers.
Net Sales to External Customers
(in millions)
Three Months
Ended
September 30, 2022
Three Months
Ended
September 30, 2021
Total
Change
Impact of
Foreign
Exchange
Total Change
Excl. Foreign
Exchange
Established Pharmaceutical Products 	$ 	1,326 $ 	1,265 	4.9 % 	(7.3)% 	12.2 %
Nutritional Products 	1,795 	2,108 	(14.9) 	(4.6) 	(10.3)
Diagnostic Products 	3,671 	3,912 	(6.2) 	(5.6) 	(0.6)
Medical Devices 	3,615 	3,632 	(0.5) 	(6.9) 	6.4
Total Reportable Segments 	10,407 	10,917 	(4.7) 	(6.0) 	1.3
Other 	3 	11 	n/m 	n/m 	n/m
Net Sales 	$ 	10,410 $ 	10,928 	(4.7) 	(6.0) 	1.3
Total U.S. 	$ 	4,094 $ 	4,368 	(6.3) 	— 	(6.3)
Total International 	$ 	6,316 $ 	6,560 	(3.7) 	(10.0) 	6.3
Net Sales to External Customers
(in millions)
Nine Months Ended
September 30, 2022
Nine Months Ended
September 30, 2021
Total
Change
Impact of
Foreign
Exchange
Total Change
Excl. Foreign
Exchange
Established Pharmaceutical Products 	$ 	3,696 $ 	3,515 	5.2 % 	(6.4)% 	11.6 %
Nutritional Products 	5,642 	6,252 	(9.8) 	(3.4) 	(6.4)
Diagnostic Products 	13,279 	11,173 	18.9 	(4.2) 	23.1
Medical Devices 	10,937 	10,618 	3.0 	(5.4) 	8.4
Total Reportable Segments 	33,554 	31,558 	6.3 	(4.7) 	11.0
Other 	8 	49 	n/m 	n/m 	n/m
Net Sales 	$ 	33,562 $ 	31,607 	6.2 	(4.7) 	10.9
Total U.S. 	$ 	13,923 $ 	11,787 	18.1 	— 	18.1
Total International 	$ 	19,639 $ 	19,820 	(0.9) 	(7.4) 	6.5
Notes:
In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average
foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
n/m = Percent change is not meaningful
22

-- 22 of 34 --

Table of Contents
The 1.3 percent increase in total net sales during the third quarter of 2022, excluding the impact of foreign exchange, reflected growth in the Medical
Devices and Established Pharmaceutical Products segments partially offset by lower Nutritional Products sales as well as a year-over-year decline in
COVID-19 testing-related revenues. Abbott’s COVID-19 testing-related sales totaled approximately $1.7 billion during the third quarter of 2022 and
approximately $1.9 billion during the third quarter of 2021. Excluding the impact of COVID-19 testing-related sales, Abbott’s total net sales decreased 3.1
percent. Excluding the impacts of COVID-19 testing-related sales and foreign exchange, Abbott’s total net sales increased 3.2 percent. Abbott’s net sales
were unfavorably impacted by changes in foreign exchange rates in the third quarter as the relatively stronger U.S. dollar decreased total international sales
by 10.0 percent and total sales by 6.0 percent.
The 10.9 percent increase in total net sales during the first nine months of 2022, excluding the impact of foreign exchange, reflected demand for Abbott’s
rapid diagnostic tests to detect COVID-19 as well as growth in the Medical Devices and Established Pharmaceutical Products segments partially offset by
lower Nutritional Products sales. Abbott’s COVID-19 testing-related sales totaled approximately $7.3 billion during the first nine months of 2022 and
approximately $5.4 billion during the first nine months of 2021. Excluding the impact of COVID-19 testing-related sales, Abbott’s total net sales increased
0.1 percent. Excluding the impacts of COVID-19 testing-related sales and foreign exchange, Abbott’s total net sales increased 4.9 percent. Abbott’s net
sales were unfavorably impacted by changes in foreign exchange rates in the first nine months as the relatively stronger U.S. dollar decreased total
international sales by 7.4 percent and total sales by 4.7 percent.
Due to the unpredictability of the duration and impact of the current COVID-19 pandemic, the future extent to which the COVID-19 pandemic will have a
material effect on Abbott’s business, financial condition or results of operations is uncertain.
The table below provides detail by sales category for the nine months ended September 30. Percent changes are versus the prior year and are based on
unrounded numbers.
(in millions)
Sept. 30,
2022
Sept. 30,
2021
Total
Change
Impact of
Foreign
Exchange
Total Change
Excl. Foreign
Exchange
Established Pharmaceutical Products —
Key Emerging Markets 	$ 	2,826 $ 	2,672 	5.8 % 	(6.4)% 	12.2 %
Other Emerging Markets 	870 	843 	3.2 	(6.3) 	9.5
Nutritionals —
International Pediatric Nutritionals 	1,491 	1,637 	(8.9) 	(4.3) 	(4.6)
U.S. Pediatric Nutritionals 	1,108 	1,622 	(31.7) 	— 	(31.7)
International Adult Nutritionals 	2,027 	1,987 	2.0 	(7.0) 	9.0
U.S. Adult Nutritionals 	1,016 	1,006 	1.0 	— 	1.0
Diagnostics —
Core Laboratory 	3,624 	3,780 	(4.1) 	(5.7) 	1.6
Molecular 	815 	1,082 	(24.7) 	(2.8) 	(21.9)
Point of Care 	394 	401 	(1.6) 	(1.2) 	(0.4)
Rapid Diagnostics 	8,446 	5,910 	42.9 	(3.8) 	46.7
Medical Devices —
Rhythm Management 	1,605 	1,657 	(3.2) 	(4.5) 	1.3
Electrophysiology 	1,440 	1,403 	2.6 	(5.6) 	8.2
Heart Failure 	690 	650 	6.2 	(2.4) 	8.6
Vascular 	1,878 	1,976 	(5.0) 	(4.9) 	(0.1)
Structural Heart 	1,271 	1,191 	6.7 	(6.1) 	12.8
Neuromodulation 	568 	584 	(2.7) 	(2.1) 	(0.6)
Diabetes Care 	3,485 	3,157 	10.4 	(7.0) 	17.4
23

-- 23 of 34 --

Table of Contents
Excluding the unfavorable effect of foreign exchange, sales in the Key Emerging Markets for Established Pharmaceutical Products increased 12.2 percent
in the first nine months of 2022, led by double-digit growth in several countries, including India and China, and therapeutic areas, including
gastroenterology, central nervous system/pain management, and respiratory products. Other Emerging Markets, excluding the effect of foreign exchange,
increased by 9.5 percent in the first nine months of 2022.
International Pediatric Nutritional sales, excluding the effect of foreign exchange, decreased 4.6 percent in the first nine months of 2022 versus the
comparable 2021 period. The decrease reflects the impact of challenging market dynamics in the infant category in Greater China partially offset by higher
sales volumes in various countries in Southeast Asia and Latin America. International Adult Nutritional sales, excluding the effect of foreign exchange,
increased 9.0 percent, reflecting double digit growth of the Ensure and Glucerna brands in several countries in Southeast Asia and China. In the first nine
months of 2022, U.S. Adult Nutritional sales increased 1.0 percent.
In U.S. Pediatric Nutritionals, Abbott initiated a voluntary recall in February 2022 of certain infant powder formula products manufactured at its facility in
Sturgis, Michigan and stopped production at the facility. On May 16, 2022, Abbott entered into a consent decree with the U.S. Food and Drug
Administration (FDA) on the steps necessary to resume production and maintain the Sturgis facility and operations. On July 1, Abbott restarted partial
production at the facility starting with its specialty formula EleCare and metabolic formulas. Subsequently, Abbott restarted Similac production. The
consent decree does not affect any other Abbott plant or operation.
During the first three quarters of 2022, Abbott took various actions to mitigate the impact of the recall on the supply of formula in the U.S. These actions
included the shipment of infant formula powder into the U.S. from Abbott's FDA-registered facility in Ireland; prioritization of infant formula production at
its Columbus, Ohio facility; conversion of other liquid manufacturing lines into manufacturing Similac liquid ready-to-feed product; increased production
of powder infant formula at its Casa Grande, Arizona manufacturing site; and importation of product from its facility in Spain as permitted by the FDA.
The 31.7 percent decrease in U.S. Pediatric Nutritional sales in the first nine months of 2022 reflects the impact of the recall and the Sturgis production
stoppage partially offset by increased demand for Abbott’s Pedialyte products. U.S. sales of infant powder formula brands associated with the recall were
$277 million and $900 million in the first nine months of 2022 and 2021, respectively.
The 23.1 percent increase in Diagnostic Products sales in the first nine months of 2022, excluding the impact of foreign exchange, was driven by demand
for Abbott’s portfolio of COVID-19 tests in Rapid Diagnostics and growth in routine diagnostic testing in Molecular Diagnostics. In Core Laboratory
Diagnostics, sales increased 1.6 percent in the first nine months of 2022, excluding the effect of foreign exchange, due to the higher volume of routine
diagnostic testing from the continued roll-out of the Alinity platform and an expanded menu of tests. These increases were partially offset by lower sales
of Abbott’s laboratory-based tests for the detection of COVID-19 IgG and IgM antibodies, which determine if someone was previously infected with the
COVID-19 virus, as well as market disruptions in China due to COVID-19 quarantine restrictions in various cities primarily during the second quarter of
2022. In the first nine months of 2022 and 2021, Core Laboratory Diagnostics IgG and IgM antibody testing-related sales on Abbott’s ARCHITECT and
Alinity i platforms were $51 million and $159 million, respectively. In the first nine months of 2022, Core Laboratory Diagnostics sales decreased 1.3
percent, excluding COVID-19 testing-related sales, and increased 4.6 percent, excluding the impact of foreign exchange and COVID-19 testing-related
sales.
The 21.9 percent decrease in Molecular Diagnostics sales in the first nine months of 2022, excluding the effect of foreign exchange, was driven by lower
demand for Abbott’s laboratory-based molecular tests for COVID-19 partially offset by growth in the base business from increased routine molecular
testing. In the first nine months of 2022 and 2021, Molecular Diagnostics COVID-19 testing-related sales were $375 million and $699 million,
respectively. In the first nine months of 2022, Molecular Diagnostics sales increased 14.9 percent, excluding COVID-19 testing-related sales, and increased
19.4 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.
In Rapid Diagnostics, sales increased 46.7 percent in the first nine months of 2022, excluding the effect of foreign exchange, due to the demand for
Abbott’s COVID-19 tests on its rapid testing platforms, including the Panbio system, the ID NOW platform, and the BinaxNOW COVID-19 Ag Card
test. In the first nine months of 2022 and 2021, Rapid Diagnostics COVID-19 testing-related sales were $6.9 billion and $4.5 billion, respectively. In the
first nine months of 2022, Rapid Diagnostics sales increased 11.8 percent, excluding COVID-19 testing-related sales, and increased 14.6 percent, excluding
the impact of foreign exchange and COVID-19 testing-related sales. These increases reflect higher sales
® 	®
® 	®
®
®
® 	® 	®
24

-- 24 of 34 --

Table of Contents
of ID NOW tests for flu, strep, and respiratory syncytial virus (RSV) as well as growth in various other Rapid Diagnostics products.
Excluding the effect of foreign exchange, total Medical Devices sales grew 8.4 percent in the first nine months of 2022, driven by growth in Diabetes Care,
Electrophysiology, Structural Heart and Heart Failure. Growth in Diabetes Care sales was driven by continued growth of FreeStyle Libre , Abbott’s
continuous glucose monitoring system, in the U.S. and internationally. FreeStyle Libre sales totaled $3.1 billion in the first nine months of 2022, which
reflected a 22.8 percent increase, excluding the effect of foreign exchange, over the first nine months of 2021 when FreeStyle Libre sales totaled $2.7
billion. During the third quarter of 2022, Abbott launched its FreeStyle Libre 3 system in the U.S., which automatically delivers up-to-the-minute glucose
readings and 14-day accuracy in a wearable sensor.
During the first nine months of 2022, procedure volumes across Abbott’s cardiovascular and neuromodulation businesses were negatively impacted by new
surges of COVID-19 in various geographies as well as intermittent COVID-19 lockdown restrictions in China and healthcare staffing challenges
throughout the nine months. Despite such challenges, overall volume trends improved in several businesses versus the first nine months of 2021. In
Electrophysiology, the 8.2 percent growth, excluding the effect of foreign exchange, reflects the increase in procedure volumes and the continued roll‑out
of Abbott’s EnSite X EP System with Ensite Omnipolar Technology (OT), a new cardiac mapping platform available in the U.S., Japan and across
Europe. In January 2022, Abbott announced FDA clearance for the EnSite X EP System with EnSite OT. The system leverages the Advisor HD Grid
Catheter to provide a 360‑degree view of the heart without regard to the orientation of the catheter in the heart.
Growth in Structural Heart during the first nine months of 2022, excluding the effect of foreign exchange, was 12.8 percent, driven by growth across
several areas of the business, including Amplatzer Amulet Left Atrial Appendage Occluder, which offers immediate closure of the left atrial appendage,
an area in the heart where blood clots can form and MitraClip , Abbott's market-leading device for the minimally invasive treatment of mitral regurgitation,
a leaky heart valve. In Vascular, sales during the first nine months of 2022, excluding the impact of foreign exchange, were virtually unchanged as higher
endovascular sales were offset by the negative effect of lower average pricing for drug-eluting stents (DES) in the U.S. and a lag in the recovery of
percutaneous coronary intervention case rates compared to many other cardiovascular procedures.
In the first nine months of 2022, Medical Devices received various other product approvals. In February 2022, Abbott received FDA approval for an
expanded indication for its CardioMEMS HF system, a small implantable sensor and remote monitoring system that can detect early warning signs of
worsening heart failure. In April 2022, Abbott announced FDA approval for its Aveir single-chamber leadless pacemaker for the treatment of patients in
the U.S. with slow heart rhythms.
The gross profit margin percentage was 50.7 percent for the third quarter of 2022 compared to 54.8 percent for the third quarter of 2021. The decrease
reflects the continued impact of the voluntary product recall and Sturgis manufacturing stoppage in the Nutritional business during the first half of 2022 as
well as the prioritization of infant formula sales related to the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC). The
decrease also reflects higher manufacturing and supply chain costs across Abbott's businesses, including inflation, commodities and distribution expenses
as well as lower COVID-19 testing-related sales in 2022 and the nonrecurrence of a favorable change in estimate in the third quarter of 2021 related to a
previously recognized restructuring plan.
The gross profit margin was 52.1 percent for the first nine months of 2022 compared to 51.6 percent for the first nine months of 2021. The increase reflects
the nonrecurrence of 2021 restructuring charges and the impact of higher sales of COVID-19 rapid tests during the first nine months of 2022. These
favorable impacts were partially offset by the impact of the voluntary product recall and Sturgis manufacturing stoppage in the Nutritional business as well
as higher manufacturing and supply chain costs across Abbott's businesses, including inflation and higher commodity and distribution expenses. The future
extent to which inflation, supply chain disruptions, and unfavorable foreign exchange rates will have a material effect on Abbott's operating results is
uncertain.
Research and development (R&D) expenses increased $110 million, or 16.2 percent, in the third quarter of 2022 and increased $183 million, or 9.2 percent,
in the first nine months of 2022 compared to the prior year. The increase in the third quarter primarily reflects the impairment of certain in-process R&D
intangible assets in the third quarter of 2022. The increase in the first nine months was also driven by higher spending on various projects to advance
products in development partially offset by the favorable impact of foreign exchange.
®
®
® 	®
®_ 	®
®
®
®
25

-- 25 of 34 --

Table of Contents
Selling, general and administrative (SG&A) expenses decreased $36 million, or 1.3 percent, in the third quarter of 2022 compared to the prior year as
higher selling and marketing spending to drive growth across various businesses was more than offset by the favorable impact of foreign exchange. SG&A
expenses were virtually unchanged in the first nine months of 2022 compared to the prior year as higher selling and marketing spending was offset by the
nonrecurrence of certain 2021 litigation costs and the favorable impact of foreign exchange.
Other (Income) Expense, net
Other income, net increased from $74 million of income in the third quarter of 2021 to $93 million of income in the third quarter of 2022 and from $214
million of income in the first nine months of 2021 to $253 million of income in the first nine months of 2022. The increases in the third quarter and the first
nine months of 2022 were primarily due to higher income in 2022 related to the non-service cost components of net pension and post-retirement medical
benefit costs. In the first nine months of 2022, the higher year-to-date income related to the non-service cost components was partially offset by the
nonrecurrence of a gain on the sale of an equity method investment that occurred in the second quarter of 2021.
Interest Expense, net
Interest expense, net declined $37 million in the third quarter of 2022 and $61 million in the first nine months of 2022 versus 2021 due to the impact of
higher interest rates and cash and short-term investment balances on interest income and the repayment of debt in the first quarter of 2022 partially offset
by the impact of interest rate hedge contracts related to certain fixed-rate debt.
Taxes on Earnings
Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first nine months of 2022 and 2021, taxes
on earnings include approximately $36 million and $97 million, respectively, in excess tax benefits associated with share-based compensation. In the first
nine months of 2022, taxes on earnings also include approximately $20 million of tax expense as the result of the resolution of various tax positions related
to prior years.
Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount
of gross unrecognized tax benefits may decrease approximately $75 million to $100 million, including cash adjustments, within the next twelve months as
a result of concluding various domestic and international tax matters.
Liquidity and Capital Resources September 30, 2022 Compared with December 31, 2021
The decrease in cash and cash equivalents from $9.8 billion at December 31, 2021 to $9.6 billion at September 30, 2022 primarily reflects share
repurchases, the payment of dividends, capital expenditures, and the repayment of debt partially offset by the cash generated from operations in the first
nine months of 2022. Working capital was $11.5 billion at September 30, 2022 and $11.1 billion at December 31, 2021. The increase in working capital in
2022 primarily reflects an increase in inventory partially offset by an increase in the current portion of long-term debt and a decrease in cash and cash
equivalents.
In the Condensed Consolidated Statement of Cash Flows, Net cash from operating activities for the first nine months of 2022 totaled approximately $7.3
billion, a decrease of $211 million from the prior year primarily due to an increased investment in working capital partially offset by higher operating
earnings. Net cash from operating activities includes $362 million of pension contributions and the payment of cash taxes of approximately $987 million in
2022. Net cash from operating activities includes $366 million of pension contributions and the payment of cash taxes of approximately $990 million in
2021.
On March 15, 2022, Abbott repaid the $750 million outstanding principal amount of its 2.55% Notes upon maturity.
In September 2019, the board of directors authorized the early redemption of up to $5 billion of outstanding long-term notes. As of September 30, 2022,
$2.15 billion of the $5 billion authorization remains available.
At September 30, 2022, Abbott’s long-term debt rating was AA- by Standard & Poor’s Corporation and A1 by Moody’s Investors Service. Abbott expects
to maintain an investment grade rating. Abbott has readily available financial resources, including lines of credit of $5.0 billion which expire in 2025.
26

-- 26 of 34 --

Table of Contents
In December 2021, the board of directors authorized the repurchase of up to $5 billion of Abbott’s common shares from time to time. The new
authorization was in addition to the $1.081 billion portion of the share repurchase program authorized in 2019 that was unused as of December 31, 2021. In
the first nine months of 2022, Abbott repurchased 25.7 million of its common shares for $2.965 billion which fully utilized the authorization remaining
under the 2019 share repurchase program and a portion of the 2021 authorization. As of September 30, 2022, $3.116 billion remains available for
repurchase under the 2021 repurchase program.
In each of the first three quarters of 2022, Abbott declared a quarterly dividend of $0.47 per share on its common shares, which represents an increase of
4.4 percent over the $0.45 per share dividend declared in each of the first three quarters of 2021.
Legislative Issues
Abbott’s primary markets are highly competitive and subject to substantial government regulations throughout the world. Abbott expects debate to continue
over the availability, method of delivery, and payment for health care products and services. It is not possible to predict the extent to which Abbott or the
health care industry in general might be adversely affected by these factors in the future. A more complete discussion of these factors is contained in Item
1, Business, and Item 1A, Risk Factors, in the 2021 Annual Report on Form 10-K.
Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements
Under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Abbott cautions that any forward-looking statements made by
Abbott are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements.
Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our
Annual Report on Form 10-K for the year ended December 31, 2021, and are incorporated herein by reference. Abbott undertakes no obligation to release
publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
27

-- 27 of 34 --

Table of Contents
PART I. FINANCIAL INFORMATION
Item 4. Controls and Procedures
(a) Evaluation of disclosure controls and procedures. The Chief Executive Officer, Robert B. Ford, and Chief Financial Officer, Robert E. Funck,
Jr., evaluated the effectiveness of Abbott Laboratories’ disclosure controls and procedures as of the end of the period covered by this report, and
concluded that Abbott Laboratories’ disclosure controls and procedures were effective to ensure that information Abbott is required to disclose
in the reports that it files or submits with the Securities and Exchange Commission (the “Commission”) under the Securities Exchange Act of
1934 (the “Exchange Act”) is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and
forms, and to ensure that information required to be disclosed by Abbott in the reports that it files or submits under the Exchange Act is
accumulated and communicated to Abbott’s management, including its principal executive officer and principal financial officer, as appropriate
to allow timely decisions regarding required disclosure.
(b) Changes in internal control over financial reporting. During the quarter ended September 30, 2022, there were no changes in Abbott’s internal
control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to
materially affect, Abbott’s internal control over financial reporting.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
Abbott is involved in various claims, legal proceedings and investigations as described in our Annual Report on Form 10-K for the year ended
December 31, 2021 and our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
(c) Issuer Purchases of Equity Securities
Period
(a) Total
Number of
Shares (or
Units)
Purchased
(b) Average
Price Paid per
Share (or
Unit)
(c) Total Number
of Shares (or
Units) Purchased
as Part of
Publicly
Announced Plans
or Programs
(d) Maximum
Number (or
Approximate
Dollar Value) of
Shares (or Units)
that May Yet Be
Purchased Under
the Plans or
Programs
July 1, 2022 - July 31, 2022 	— 	$ 	— 	— $ 	3,981,169,070
August 1, 2022 - August 31, 2022 	1,050,000 	102.567 	1,050,000 	3,873,473,475
September 1, 2022 - September 30, 2022 	7,363,597 	102.895 	7,363,597 	3,115,796,433
Total 	8,413,597 	$ 	102.854 	8,413,597 $ 	3,115,796,433
______________________________________
1. These shares do not include the shares surrendered to Abbott to satisfy tax withholding obligations in connection with the vesting of restricted stock or
restricted stock units.
2. On December 10, 2021, the board of directors authorized the repurchase of up to $5 billion of Abbott common shares, from time to time.
(1) 	(2)
28

-- 28 of 34 --

Table of Contents
Item 6. Exhibits
Exhibit No. 	Exhibit
3.1 	By-Laws of Abbott Laboratories, as amended and restated effective September 15, 2022, filed as Exhibit 3.1 to the Abbott
Laboratories Current Report on Form 8-K filed on September 15, 2022.
31.1 	Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).
31.2 	Certification of Chief Financial Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).
Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed” under the Securities Exchange Act of 1934.
32.1 	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-
Oxley Act of 2002.
32.2 	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-
Oxley Act of 2002.
101 	The following financial statements and notes from the Abbott Laboratories Quarterly Report on Form 10-Q for the quarter and nine
months ended September 30, 2022, formatted in Inline XBRL: (i) Condensed Consolidated Statement of Earnings; (ii) Condensed
Consolidated Statement of Comprehensive Income; (iii) Condensed Consolidated Balance Sheet; (iv) Condensed Consolidated
Statement of Shareholders’ Investment; (v) Condensed Consolidated Statement of Cash Flows; and (vi) Notes to the Condensed
Consolidated Financial Statements.
104 	Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document and included in Exhibit
101).
29

-- 29 of 34 --

Table of Contents
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ABBOTT LABORATORIES
By: 	/s/ Robert E. Funck, Jr.
Robert E. Funck, Jr.
Executive Vice President, Finance
and Chief Financial Officer
Date: November 1, 2022
30

-- 30 of 34 --

Exhibit 31.1
Certification of Chief Executive Officer
Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))
I, Robert B. Ford, certify that:
1. 	I have reviewed this quarterly report on Form 10-Q of Abbott Laboratories;
2. 	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
3. 	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of Abbott as of, and for, the periods presented in this report;
4. 	Abbott’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for
Abbott and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to Abbott, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of Abbott’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in Abbott’s internal control over financial reporting that occurred during Abbott’s most recent fiscal
quarter that has materially affected, or is reasonably likely to materially affect, Abbott’s internal control over financial reporting; and
5. 	Abbott’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to Abbott’s
auditors and the audit committee of Abbott’s board of directors:
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect Abbott’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in Abbott’s internal control
over financial reporting.
Date: November 1, 2022 	/s/ Robert B. Ford
Robert B. Ford
Chairman of the Board and Chief Executive Officer

-- 31 of 34 --

Exhibit 31.2
Certification of Chief Financial Officer
Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))
I, Robert E. Funck, Jr., certify that:
1. 	I have reviewed this quarterly report on Form 10-Q of Abbott Laboratories;
2. 	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
3. 	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of Abbott as of, and for, the periods presented in this report;
4. 	Abbott’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for
Abbott and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to Abbott, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of Abbott’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in Abbott’s internal control over financial reporting that occurred during Abbott’s most recent fiscal
quarter that has materially affected, or is reasonably likely to materially affect, Abbott’s internal control over financial reporting; and
5. 	Abbott’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to Abbott’s
auditors and the audit committee of Abbott’s board of directors:
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect Abbott’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in Abbott’s internal control
over financial reporting.
Date: November 1, 2022 	/s/ Robert E. Funck, Jr.
Robert E. Funck, Jr.
Executive Vice President, Finance
and Chief Financial Officer

-- 32 of 34 --

Exhibit 32.1
Certification Pursuant To
18 U.S.C. Section 1350
As Adopted Pursuant To
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report of Abbott Laboratories (the “Company”) on Form 10-Q for the period ended September 30, 2022 as filed
with the Securities and Exchange Commission (the “Report”), I, Robert B. Ford, Chairman of the Board and Chief Executive Officer of the Company,
certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ Robert B. Ford
Robert B. Ford
Chairman of the Board and Chief Executive Officer
November 1, 2022
A signed original of this written statement required by Section 906 has been provided to Abbott Laboratories and will be retained by Abbott Laboratories
and furnished to the Securities and Exchange Commission or its staff upon request.

-- 33 of 34 --

Exhibit 32.2
Certification Pursuant To
18 U.S.C. Section 1350
As Adopted Pursuant To
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report of Abbott Laboratories (the “Company”) on Form 10-Q for the period ended September 30, 2022 as filed
with the Securities and Exchange Commission (the “Report”), I, Robert E. Funck, Jr., Executive Vice President, Finance and Chief Financial Officer of the
Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ Robert E. Funck, Jr.
Robert E. Funck, Jr.
Executive Vice President, Finance
and Chief Financial Officer
November 1, 2022
A signed original of this written statement required by Section 906 has been provided to Abbott Laboratories and will be retained by Abbott Laboratories
and furnished to the Securities and Exchange Commission or its staff upon request.

-- 34 of 34 --